The global bronchial biopsy devices market size is expected to reach USD 1.02 billion by 2030, growing at a CAGR of 7.39% from 2024 to 2030. One of the major factors contributing to the growth of the market is the rising utilization of bronchial biopsy devices for diagnosing respiratory diseases and the increasing adoption of disposable devices. Moreover, rapid technological advancements and increasing awareness and screening regarding respiratory diseases also contribute to market expansion.
Advancements in medical technology are significantly driving the growth of the market by improving the precision, safety, and effectiveness of diagnostic procedures. Innovations such as EBUS-TBNA enable more accurate sampling of lung tissue, especially in difficult-to-reach areas. These minimally invasive techniques minimize patient discomfort, reduce the risk of complications, and shorten recovery times compared to traditional surgical methods. In addition, companies are entering the market with technologically advanced products to establish a strong presence. For instance, in May 2021, Olympus launched the BF-UC190F endobronchial ultrasound (EBUS) bronchoscope for lung cancer diagnosis and staging, thereby expanding its product portfolio.
Moreover, the increasing awareness and screening initiatives led by various organizations are significantly driving the demand for bronchial biopsy devices. With lung cancer being one of the most prevalent and deadly forms of cancer globally, organizations such as the American Lung Association and the WHO have intensified their efforts to promote early detection and diagnosis. In August 2024, in recognition of World Lung Cancer Day, the Forum of International Respiratory Societies, with the Global Initiative for Asthma as a founding member, emphasized the critical need for increased awareness, early screening, and improved access to lung cancer diagnosis & treatment.
Furthermore, the COVID-19 pandemic had a moderately negative impact on the bronchial biopsy device market, as evidenced by the disruption in lung cancer diagnosis and treatment observed during the early months of the pandemic. According to a study conducted by Elsevier España SLU, in July 2021, at a referral University Hospital in Spain, the mandatory confinement from March 23rd to June 21st, 2020, led to a substantial decrease in the number of lung cancer diagnoses. This decline was attributed to the cancellation or delay of medical consultations, diagnostic tests, and non-essential procedures, which resulted in a reduced number of lung biopsies & screening visits.
This product will be delivered within 1-3 business days.
Advancements in medical technology are significantly driving the growth of the market by improving the precision, safety, and effectiveness of diagnostic procedures. Innovations such as EBUS-TBNA enable more accurate sampling of lung tissue, especially in difficult-to-reach areas. These minimally invasive techniques minimize patient discomfort, reduce the risk of complications, and shorten recovery times compared to traditional surgical methods. In addition, companies are entering the market with technologically advanced products to establish a strong presence. For instance, in May 2021, Olympus launched the BF-UC190F endobronchial ultrasound (EBUS) bronchoscope for lung cancer diagnosis and staging, thereby expanding its product portfolio.
Moreover, the increasing awareness and screening initiatives led by various organizations are significantly driving the demand for bronchial biopsy devices. With lung cancer being one of the most prevalent and deadly forms of cancer globally, organizations such as the American Lung Association and the WHO have intensified their efforts to promote early detection and diagnosis. In August 2024, in recognition of World Lung Cancer Day, the Forum of International Respiratory Societies, with the Global Initiative for Asthma as a founding member, emphasized the critical need for increased awareness, early screening, and improved access to lung cancer diagnosis & treatment.
Furthermore, the COVID-19 pandemic had a moderately negative impact on the bronchial biopsy device market, as evidenced by the disruption in lung cancer diagnosis and treatment observed during the early months of the pandemic. According to a study conducted by Elsevier España SLU, in July 2021, at a referral University Hospital in Spain, the mandatory confinement from March 23rd to June 21st, 2020, led to a substantial decrease in the number of lung cancer diagnoses. This decline was attributed to the cancellation or delay of medical consultations, diagnostic tests, and non-essential procedures, which resulted in a reduced number of lung biopsies & screening visits.
Bronchial Biopsy Devices Market Report Highlights
- Based on product, the transbronchial needle aspiration (TBNA) needles segment held the largest revenue share of 62.18% in 2023 and is expected to register growth at the highest CAGR over the forecast period. Moreover, the cryobiopsy devices (cryoprobes) segment is anticipated to grow significantly over the forecast period
- The EBUS-TBNA segment held the largest market share in 2023, as it is a minimally invasive technique that allows for collecting tissue samples from the lungs and surrounding lymph nodes without requiring major surgery
- In 2023, North America dominated the market with a share of over 40%, owing to the robust healthcare infrastructure and rising adoption of innovative diagnostic tools
- Key players in the market are adopting several strategies such as partnership, collaboration, and product launch to expand their offering and increase their market share. For instance, in May 2024, Cook Medical, introduced AcuCore, a next-generation EchoTip AcuCore Endoscopic Ultrasound (EUS) Biopsy Needle in the U.S. It is employed with an ultrasound endoscope for FNB of extramural and submucosal lesions lymph nodes, mediastinal masses, and intraperitoneal masses within the GI tract
The leading players in the Bronchial Biopsy Devices market include:
- Medtronic
- Boston Scientific Corporation
- CONMED Corporation
- Olympus Corporation
- Becton, Dickinson and Company (BD)
- Cook Medical
- Telemed Systems, Inc.
- HOBBS MEDICAL INC
- Argon Medical Devices (WEIGAO GROUP)
- Horizons International Corp.
- Erbe Elektromedizin GmbH.
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Market Variables, Trends, & Scope
Chapter 4. Product Business Analysis
Chapter 5. Regional Estimates & Trend Analysis by Component
Chapter 6. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The leading players in the Bronchial Biopsy Devices market include:- Medtronic
- Boston Scientific Corporation
- CONMED Corporation
- Olympus Corporation
- Becton, Dickinson and Company (BD)
- Cook Medical
- Telemed Systems, Inc.
- HOBBS MEDICAL INC
- Argon Medical Devices (WEIGAO GROUP)
- Horizons International Corp.
- Erbe Elektromedizin GmbH.
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 100 |
Published | September 2024 |
Forecast Period | 2023 - 2030 |
Estimated Market Value ( USD | $ 626.83 Million |
Forecasted Market Value ( USD | $ 1020 Million |
Compound Annual Growth Rate | 7.3% |
Regions Covered | Global |
No. of Companies Mentioned | 12 |